The Pharmacological Potential of Apigenin and Diosmetin as a Novel Treatment for Chronic Lymphedema
ISEF · 2015 Biomedical Engineering Fourth Award
Overview
Chronic lymphedema is a progressive, disabling condition characterized by regional bodily accumulation of protein-rich interstitial fluid. It affects over 100 million worldwide, yet no pharmacological treatment exists. This novel investigation was conducted to develop the first natural pharmaceutical to treat lymphedema by examining the ability of flavonoids in vitro and ex vivo to target inflammation, abnormal lymphatic endothelial cell (LEC) layer permeability and impairment of lymphatic collecting vessel contractility that accompany lymphedema. Utilizing a new approach, 4 tests were conducted on basal and LPS-stimulated LECs, macrophages and lymphatic collecting vessels. RT-PCR assessed inflammatory gene expression (TNFa, COX-2) of cells and collecting vessels. Permeability and wound scratch assays assessed LEC layer permeability and proliferation. Pressurized vessel assays assessed lymphatic smooth muscle contractility. 1µM flavonoid treatments exhibited anti-inflammatory effects on LECs, suppressing COX-2 and TNFa when applied for 24 hours and as 2-hour pretreatments. Treatments also exhibited anti-inflammatory effects on macrophages. Apigenin reduced LEC layer permeability and promoted LEC proliferation. Apigenin restored contractility of inflamed lymphatic collecting vessels. Among many causes, the leading cause of lymphedema is filariasis, a parasitic infection threatening 1.3 billion, primarily in developing countries. Due to impoverished situations of endemic regions, physical therapy is unavailable for patients with filarial-lymphedema. Apigenin was determined to possess promising properties to target the factors that characterize lymphedema. It is low-cost and available to those in both developed countries and regions where medical support is minimal.
Awards (1)
- Fourth Award of $500 $500
Competition history
- ISEF 2015
Resources
Related projects
ISEF · 2014
Treat Chronic Lymphedema: The Effects of Apigenin, Diosmetin, and Chicoric Acid on TNF-Alpha and COX-2 Levels of Stimulated RAW 264.7 Macrophages
ISEF · 2022
Determination of Therapeutic Potential of Apigenin on Philadelphia Negative Acute Lymphoblastic Leukemia
ISEF · 2021
Anti-inflammatory Effects of the Biflavonoid Biflata on Macrophage
ISEF · 2018
Inhibition of LPS-Induced Inflammation in Macrophages Through Natural Anti-Inflammatory Compounds
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair